Endothelin antagonist as add-on treatment for proteinuria in diabetic nephropathy: is there light at the end of the tunnel?
After the seminal discovery by Yanagisawa et al. [1][1] of the endothelial cell-derived vasopressor endothelin-1 (ET) and eventually the identification of two other isoforms, inhibitors of the ET receptors (ETA, ETB1, and ETB2) were high on the list of therapeutic drugs for the pharmaceutical
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
March 31, 2011
|
| In: |
Journal of the American Society of Nephrology
Year: 2011, Volume: 22, Issue: 4, Pages: 593-595 |
| ISSN: | 1533-3450 |
| DOI: | 10.1681/ASN.2011020158 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1681/ASN.2011020158 Verlag, lizenzpflichtig, Volltext: https://jasn.asnjournals.org/content/22/4/593 
|
| Author Notes: | Eberhard Ritz and René R. Wenzel |
| Summary: | After the seminal discovery by Yanagisawa et al. [1][1] of the endothelial cell-derived vasopressor endothelin-1 (ET) and eventually the identification of two other isoforms, inhibitors of the ET receptors (ETA, ETB1, and ETB2) were high on the list of therapeutic drugs for the pharmaceutical |
|---|---|
| Item Description: | Gesehen am 16.09.2022 |
| Physical Description: | Online Resource |
| ISSN: | 1533-3450 |
| DOI: | 10.1681/ASN.2011020158 |